Last reviewed · How we verify

Nicorette Gum

University of Miami · FDA-approved active Small molecule

Nicotine binds to nicotinic acetylcholine receptors in the brain, providing nicotine replacement to reduce cravings and withdrawal symptoms during smoking cessation.

Nicotine binds to nicotinic acetylcholine receptors in the brain, providing nicotine replacement to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation aid, Reduction of cigarette smoking.

At a glance

Generic nameNicorette Gum
Also known asNRT
SponsorUniversity of Miami
Drug classNicotinic acetylcholine receptor agonist
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaSmoking Cessation / Addiction Medicine
PhaseFDA-approved

Mechanism of action

Nicorette Gum delivers nicotine through the oral mucosa, bypassing the lungs and providing a slower, more controlled nicotine absorption compared to smoking. By activating nicotinic acetylcholine receptors, it alleviates withdrawal symptoms and reduces the rewarding effects of cigarette smoking, helping users quit. This allows smokers to gradually reduce nicotine dependence while managing behavioral and physical addiction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: